AstraZeneca stock heads into the open after a 1.2% New York drop
Published on 09/17/2026 at 07:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at USD 161.76 on the New York Stock Exchange on September 15, 2026, down 1.24% from the previous session, based on NYSE pricing data reported by MarketBeat. The move came as investors digested recent analyst commentary and pipeline news, with the shares trading below some broker targets.
September 15, 2026 in numbers
AstraZeneca plc (ISIN US6549022043, NYSE: AZN) saw its US-listed shares end the September 15, 2026 session at USD 161.76 on the New York Stock Exchange after trading within an intraday range of roughly USD 159 to USD 164, per closing data reported by MarketBeat in a recent wrap of the stock. According to that same MarketBeat-based pricing overview, the 1.24% decline on the day left AstraZeneca underperforming compared with the broader market, with the Dow Jones Industrial Average falling about 1.21% on September 16, 2026 as investors reacted to signals of further monetary tightening.
In the company’s home market, AstraZeneca’s London-listed shares traded around 122.38 GBP on September 16, 2026, modestly above a prior close of 120.24 GBP, as noted in an intraday corporate-news summary that cited London Stock Exchange data and UBS valuation work. The article from Ad-hoc-news reported that the London shares were up around 0.8% intraday, with volumes near 476,980 shares in one snapshot and a day high near 122.44 GBP, indicating solid trading activity despite the recent pullback in global equities.
The same Ad-hoc-news dispatch highlighted UBS cutting its price target on AstraZeneca to 15,200 pence from 17,600 pence while maintaining a buy recommendation, pointing to more than 25% upside from a close around 11,925 pence on September 15, 2026 and describing the shares as oversold after trial setbacks and merger speculation, as detailed further in a report from Proactive Investors. Together, these assessments framed the prior sessions as a period in which AstraZeneca’s stock faced mixed pressures, with macro headwinds from rate concerns on the one hand and supportive broker commentary on valuation and pipeline potential on the other.
Today’s drivers around AstraZeneca
Heading into today’s US session on September 17, 2026, AstraZeneca does not have a widely flagged earnings release or annual meeting date falling on this specific day in mainstream calendars over the past week, but the stock remains sensitive to broader market moves linked to interest-rate expectations and sector sentiment, particularly ahead of forthcoming central bank decisions that have recently weighed on global equities, as described in coverage of US index moves by outlets such as Aju Business Daily. Analyst commentary from UBS, including the cut to a 15,200 pence price target while reiterating a buy stance, continues to shape the narrative around AstraZeneca’s valuation and risk-reward profile today, as emphasized by Proactive Investors, and investors are likely to monitor any further trial updates or strategic news that could alter that assessment over the coming sessions.
